{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.13","value":"71.7"},{"groupId":"OG001","spread":"22.38","value":"71.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"386"}],"units":"Participants"}],"title":"ET, Week 4 (n=383,386)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.62","value":"73.4"},{"groupId":"OG001","spread":"19.37","value":"73.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"346"}],"units":"Participants"}],"title":"ET, Week 10 (n=321,346)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.56","value":"73.9"},{"groupId":"OG001","spread":"21.43","value":"72.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"293"}],"units":"Participants"}],"title":"ET, Week 16 (n=296,293)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.40","value":"73.0"},{"groupId":"OG001","spread":"20.43","value":"73.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"250"}],"units":"Participants"}],"title":"ET, Week 22 (n=250,250)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.00","value":"66.3"},{"groupId":"OG001","spread":"23.59","value":"58.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"FSE, Week 4 (n=340,360)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.09","value":"66.0"},{"groupId":"OG001","spread":"22.23","value":"56.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"323"}],"units":"Participants"}],"title":"FSE, Week 10 (n=298,323)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.01","value":"65.0"},{"groupId":"OG001","spread":"22.02","value":"56.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"277"}],"units":"Participants"}],"title":"FSE, Week 16 (n=274,277)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.62","value":"67.1"},{"groupId":"OG001","spread":"21.28","value":"57.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"title":"FSE, Week 22 (n=235, 232)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.49","value":"80.9"},{"groupId":"OG001","spread":"15.23","value":"79.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"title":"SWT, Week 4 (n=355,374)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.74","value":"84.5"},{"groupId":"OG001","spread":"15.15","value":"80.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"title":"SWT, Week 10 (n=309,336)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.77","value":"85.3"},{"groupId":"OG001","spread":"15.08","value":"80.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"284"}],"units":"Participants"}],"title":"SWT, Week 16 (n=287,284)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.48","value":"85.4"},{"groupId":"OG001","spread":"15.04","value":"81.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"SWT, Week 22 (n=241,240)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"386"}],"units":"Participants"}],"description":"The CTSQ assesses 3 domains related to the participant's satisfaction with cancer therapy: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Participants shared their thoughts on their cancer therapy (9 questions), their satisfaction with their most recently administered cancer therapy (6 questions), and if they would take the same cancer therapy if given the choice to do so again. All questions were assessed on a 5-point scale; 1, never; 5, always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better treatment satisfaction.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Participants missing scores at early time points were excluded from the analysis at those time points. Mean total score was calculated at each assessment week.","reportingStatus":"POSTED","timeFrame":"Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Summary of Analysis for the Cancer Treatment Satisfaction Questionnaire (CTSQ) Score at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}